Logo

CombiMatrix Signs on Galaxy Health Network for Coverage of Services

Jan 23, 2014 | staff reporter

NEW YORK (GenomeWeb News) – CombiMatrix today announced a contract with Galaxy Health Network to provide access to CombiMatrix's diagnostic laboratory services for Galaxy's 3.5 million covered lives.

Galaxy is based in Arlington, Texas and has in its provider network more than 400,000 directly contracted doctors, 2,700 hospitals, and 47,000 ancillary providers.

"This agreement further expands our reach throughout the country providing much wider access to our entire portfolio of testing services, including our CombiSNP chromosomal microarray test," CombiMatrix President and CEO Mark McDonough said in a statement.

Last month, the Irvine, Calif.-based firm announced a contract with FedMed also covering CombiMatrix's diagnostic laboratory services.

Filed under

Microarrays & Multiplexing
Diagnostics
microarrays
Invitae
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.